课题基金 / 基金详情

Clinical Protocol and Data Management

Clinical Protocol and Data Management
临床方案和数据管理
批准号:
9145406
负责人:
EDWARD A. SAUSVILLE
金额:
$12.55万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

EDWARD A. SAUSVILLE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
12.0 Abstract: Clinical Protocol and Data Management The Clinical Protocol and Data Management (CPDM) component of UMGCC comprises the personnel in the Clinical Research Management Office (CRMO), formerly defined as the Clinical Research Shared Service in the 2011 CCSG application, and the resources, including database and technical staff, supporting its operations. The CRMO participates with investigators in the various UMGCC Disease Groups or assists research support staff housed in other departments in UMB, as requested, in the design, review, implementation, monitoring, and reporting of all clinical protocols. This effort includes interactions with the Institutional Review Board (IRB) of UMB, the NCI Central IRB, the Clinical Research Committee (CRC; functioning as the Protocol Review and Monitoring System) of UMGCC, and the UMGCC Data Safety Monitoring/Quality Assurance Committee (DSM/QAC) as well as other monitoring and auditing entities. CRMO utilizes the OnCore database to track enrollment of all patients, completing case report forms for industry- sponsored trials and entering data into appropriate databases for National Clinical Trials Network and Experimental Therapeutics Clinical Trials Network NCI-sponsored studies. During the last granting period encompassing CY2010–2014, the CRMO supported 200–250 protocols/year, resulting in 112 publications. The UMGCC DSM/QAC serves the data safety monitoring function for those protocols that do not have an external data and safety monitoring board (DSMB). The DSM/QAC annually reviews safety information for accrued patients to all “greater than minimal risk” (according to UMB IRB criteria) investigator-initiated trials of any phase, all Phase I trials, and selected industry Phase II trials without a sponsor-appointed DSMB, including multi-institutional investigator-initiated trials for which UMGCC is the coordinating center. During FY2014, costs to support CPDM were $3,159,534, of which $157,278 were from the CCSG. During FY2014, costs to support the DSM/QAC were $776,002, of which $78,500 were from the CCSG.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: TREATMENT OF MELANOMA WITH WILD-TYPE P53 AND A 100B USING PENTA
  • 批准号:
    7951182
  • 项目类别:
  • 资助金额:
    $0.96万
  • 财政年份:
    2009
  • 负责人:
    EDWARD A. SAUSVILLE
  • 依托单位:
UMGCC Paul Calabresi Clinical Oncology Training Program
  • 批准号:
    8332885
  • 项目类别:
  • 资助金额:
    $106.57万
  • 财政年份:
    2008
  • 负责人:
    EDWARD A. SAUSVILLE
  • 依托单位:
UMGCC Paul Calabresi Clinical Oncology Training Program
  • 批准号:
    7928077
  • 项目类别:
  • 资助金额:
    $112.12万
  • 财政年份:
    2008
  • 负责人:
    EDWARD A. SAUSVILLE
  • 依托单位:
UMGCC Paul Calabresi Clinical Oncology Training Program
  • 批准号:
    7470184
  • 项目类别:
  • 资助金额:
    $29.5万
  • 财政年份:
    2008
  • 负责人:
    EDWARD A. SAUSVILLE
  • 依托单位:
海外基金